Abstract: Objective The aim of this study is to investigate the efficacyof cetuximab and KRAS gene mutation in the treatment of patients with primary liver cancer （PLC）.Methods A prospective study was conducted in 96 patients with PLC in our hospital from August 2014 to August 2017. All patients were treated with cisplatin,and the mutation of peripheral blood KRAS gene was detected by PCR. Logistic regression analysis was applied to find affecting efficacy factors.Results At the end of eight weeks,partial response （PR） was obtained in 59 （61.5%）,stable disease （SD） in 22 （22.9%）,and progressive diseases （PD） in 15（15.6%） patients with PLC;the blood KRAS mutation rate in 81 patients with PR/SD was 9.9%,much lower than 40.0% （P<0.05） in 15 patients with PD;the GGT-GAT and GGT-GTT mutation of condon 12 and GGC-GAC mutation of condon 13 in patients with PD were 13.3%,6.7% and 6.7%,significantly higher than 0.0%,0.0% and 0.0% （P<0.05） in patients with PR/SD;Logistic regression analysis showed that Child class,tumor type and PKRAS gene mutation were the independent factors affecting the efficacy. Conclusion The application of cetuximab in the treatment of patients with PLC might be efficacious,and the detection of blood KRAS gene mutation might be helpful for patient inclusion.

Key words: Hepatoma, Cetuximab, KRAS gene, Therapy